Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Alector, Inc. stock logo
ALEC
Alector
$1.72
+4.2%
$1.38
$0.87
$6.78
$164.99M0.74836,061 shs710,580 shs
BIOA
BioAge Labs
$4.68
+1.1%
$0.00
$2.88
$26.62
$165.99MN/A295,972 shs145,838 shs
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
$1.08
+1.9%
$0.98
$0.81
$3.02
$42.40M2.791.07 million shs465,811 shs
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
$3.63
+1.3%
$3.83
$3.36
$12.22
$144.54M1.114,608 shs1,050 shs
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Alector, Inc. stock logo
ALEC
Alector
+4.24%+16.61%+8.18%+81.05%-65.74%
BIOA
BioAge Labs
+1.08%+9.35%+467,999,900.00%+467,999,900.00%+467,999,900.00%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
+1.89%+13.56%+3.85%-2.70%-26.53%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-0.66%-2.55%-4.48%-6.33%-45.57%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Alector, Inc. stock logo
ALEC
Alector
4.1105 of 5 stars
3.13.00.04.52.62.50.0
BIOA
BioAge Labs
N/AN/AN/AN/AN/AN/AN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
1.9901 of 5 stars
3.53.00.00.02.40.00.0
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
2.4553 of 5 stars
3.85.00.00.00.00.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Alector, Inc. stock logo
ALEC
Alector
2.14
Hold$4.00132.56% Upside
BIOA
BioAge Labs
0.00
N/AN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
3.00
Buy$9.00733.33% Upside
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
3.50
Strong Buy$12.00231.03% Upside

Current Analyst Ratings Breakdown

Latest ITRM, BIOA, MOLN, and ALEC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/9/2025
Alector, Inc. stock logo
ALEC
Alector
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $10.00
5/8/2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy$9.00
(Data available from 7/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Alector, Inc. stock logo
ALEC
Alector
$100.56M1.71N/AN/A$1.29 per share1.33
BIOA
BioAge Labs
N/AN/AN/AN/A$9.01 per shareN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/A($0.15) per shareN/A
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
$2.23M65.57N/AN/A$3.99 per share0.91
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Alector, Inc. stock logo
ALEC
Alector
-$119.05M-$1.26N/AN/AN/A-139.74%-100.58%-25.15%8/6/2025 (Estimated)
BIOA
BioAge Labs
-$71.11MN/A0.00N/AN/AN/AN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$24.77M-$0.99N/AN/AN/AN/A-71.37%8/13/2025 (Estimated)
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-$61.39M-$1.92N/AN/AN/AN/A-42.20%-38.12%8/25/2025 (Estimated)

Latest ITRM, BIOA, MOLN, and ALEC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2025Q2 2025
Alector, Inc. stock logo
ALEC
Alector
-$0.45N/AN/AN/A$2.76 millionN/A
5/15/2025Q1 2025
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
-$0.3855-$0.50-$0.1145-$0.50N/AN/A
5/13/2025Q1 2025
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
-$0.14-$0.14N/A-$0.14N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Alector, Inc. stock logo
ALEC
Alector
N/AN/AN/AN/AN/A
BIOA
BioAge Labs
N/AN/AN/AN/AN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/AN/AN/AN/AN/A
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Alector, Inc. stock logo
ALEC
Alector
0.10
3.34
3.34
BIOA
BioAge Labs
N/A
13.68
13.68
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
N/A
3.72
3.58
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
N/A
15.28
15.28

Institutional Ownership

CompanyInstitutional Ownership
Alector, Inc. stock logo
ALEC
Alector
85.83%
BIOA
BioAge Labs
N/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
9.21%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
26.55%

Insider Ownership

CompanyInsider Ownership
Alector, Inc. stock logo
ALEC
Alector
9.10%
BIOA
BioAge Labs
20.82%
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
9.20%
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
5.93%
CompanyEmployeesShares OutstandingFree FloatOptionable
Alector, Inc. stock logo
ALEC
Alector
27099.99 million90.89 millionOptionable
BIOA
BioAge Labs
N/A35.85 million28.39 millionN/A
Iterum Therapeutics PLC stock logo
ITRM
Iterum Therapeutics
1040.00 million36.32 millionNot Optionable
Molecular Partners AG Sponsored ADR stock logo
MOLN
Molecular Partners
18040.38 million37.98 millionNot Optionable

Recent News About These Companies

Molecular Partners AG (MOLN) - Yahoo Finance

New MarketBeat Followers Over Time

Media Sentiment Over Time

Alector stock logo

Alector NASDAQ:ALEC

$1.72 +0.07 (+4.24%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$1.64 -0.09 (-4.94%)
As of 08:55 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Alector, Inc., a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases. The company also offers AL002, a product candidate that is in Phase II clinical trial for the treatment of Alzheimer's disease. Alector, Inc. has a collaboration agreement with Adimab, LLC for the research and development of antibodies; and a strategic collaboration agreement with GlaxoSmithKline plc for the development and commercialization of monoclonal antibodies, such as AL001 and AL101 to treat neurodegenerative diseases. The company was founded in 2013 and is headquartered in South San Francisco, California.

BioAge Labs NASDAQ:BIOA

$4.68 +0.05 (+1.08%)
As of 07/10/2025 04:00 PM Eastern

We are a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Our technology platform and differentiated human datasets enable us to identify promising targets based on insights into molecular changes that drive aging. Our primary focus is metabolic disease, one of the greatest global healthcare challenges. Azelaprag, our lead product candidate, is an orally available small molecule that has been well-tolerated in 265 individuals across eight Phase 1 clinical trials. In preclinical obesity models, azelaprag demonstrated the ability to more than double the weight loss induced by a glucagon-like-peptide-1 receptor (GLP-1R) agonist while also restoring healthy body composition and improving muscle function. These preclinical results are supported by our Phase 1b clinical trial in older adults on bed rest where we observed decreased muscle atrophy, preservation of muscle quality and improved metabolism in subjects treated with azelaprag over a 10-day period. We plan to assess azelaprag’s potential to drive significant improvements in weight loss when combined with a GLP-1R agonist in two Phase 2 clinical trials. While the results of these preclinical studies and early clinical trials have demonstrated the potential use of azelaprag for the treatment of metabolic disease, they may not be predictive of the results of later-stage clinical trials. The ongoing STRIDES clinical trial will assess azelaprag in combination with tirzepatide, marketed as Zepbound® by Eli Lilly and Company (Lilly), with topline results anticipated in the third quarter of 2025. The second Phase 2 clinical trial will assess azelaprag in combination with semaglutide, marketed as Wegovy® by Novo Nordisk, with initiation expected in the first half of 2025 and topline results expected in the second half of 2026. We believe these trials will directly support our ultimate therapeutic goal of developing an all-oral combination product for obesity. We also intend to initiate an insulin sensitivity proof-of-concept trial of azelaprag monotherapy in the first half of 2025 to support potential indication expansion. We expect to report topline results from this proof-of-concept trial in the second half of 2025. We are also developing orally available small molecule brain-penetrant NLRP3 inhibitors for the treatment of diseases driven by neuroinflammation. We anticipate submitting an Investigational New Drug application (IND) for an NLRP3 inhibitor in the second half of 2025 and, if cleared, initiating a Phase 1 clinical trial in the first half of 2026. Our approach: Targeting human aging biology to treat chronic metabolic diseases The burden of many serious and chronic diseases—including cardiovascular disease and diabetes—increases with age. However, there is substantial natural variation in the human population, resulting in a broad range of aging trajectories and outcomes, with some people experiencing much longer lifespans as well as delayed disease onset. We created our company to identify biological pathways associated with longer, healthier human lifespans and to develop pharmaceutical products that can modulate these pathways with the intent to prevent and reverse specific diseases, focusing on metabolic diseases. --- Our approach starts with human data. We examine the impact of the molecular changes that happen naturally as people age and study how these changes drive both functional decline (e.g., loss of muscle strength) and disease risk (e.g., obesity, insulin resistance, dyslipidemia, hypertension). To develop new insights into the biological drivers of aging, we have generated proprietary longitudinal human datasets based on exclusive access to a unique resource: serial biobanked human samples coupled with health records and functional measurements collected for up to 50 years, capturing individual aging trajectories measured over several decades. We analyze these samples using state-of-the-artmolecular profiling technologies, measuring thousands of biologically relevant molecules, and then apply computational tools to the resulting data to extract potential drivers of a long and healthy lifespan. --- We have selected chronic metabolic diseases as our primary focus within age related chronic diseases, given their high prevalence and resulting potential for impact on population health. Chronic metabolic diseases represent some of the largest addressable therapeutics markets. Through our approach, we expect to target outsized commercial opportunities, initially within the obesity and diabetes landscape. For instance, according to third-party estimates, the global market for GLP-1R agonists, including those used to treat diabetes, is expected to grow to $150 billion by 2031. We were incorporated under the laws of the State of Delaware on April 1, 2015, under the name BioAge Labs, Inc. Our principal executive offices are located at 1445A South 50th Street, Richmond, California.

Iterum Therapeutics stock logo

Iterum Therapeutics NASDAQ:ITRM

$1.08 +0.02 (+1.89%)
Closing price 07/10/2025 04:00 PM Eastern
Extended Trading
$1.10 +0.01 (+1.39%)
As of 08:59 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Molecular Partners stock logo

Molecular Partners NASDAQ:MOLN

$3.62 +0.05 (+1.26%)
Closing price 07/10/2025 03:05 PM Eastern
Extended Trading
$3.57 -0.06 (-1.63%)
As of 06:14 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.